ZA200307955B - Treatment of ADHD. - Google Patents
Treatment of ADHD. Download PDFInfo
- Publication number
- ZA200307955B ZA200307955B ZA200307955A ZA200307955A ZA200307955B ZA 200307955 B ZA200307955 B ZA 200307955B ZA 200307955 A ZA200307955 A ZA 200307955A ZA 200307955 A ZA200307955 A ZA 200307955A ZA 200307955 B ZA200307955 B ZA 200307955B
- Authority
- ZA
- South Africa
- Prior art keywords
- adhd
- tetrahydropyridin
- indol
- indole
- dihydro
- Prior art date
Links
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title claims description 28
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title claims description 28
- 238000011282 treatment Methods 0.000 title claims description 15
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- YVIUVYJJSZFGCX-UHFFFAOYSA-N 1-[3-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 YVIUVYJJSZFGCX-UHFFFAOYSA-N 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 3
- YVIUVYJJSZFGCX-IBGZPJMESA-N 1-[(3r)-3-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)C[C@@H]1CCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 YVIUVYJJSZFGCX-IBGZPJMESA-N 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000003368 psychostimulant agent Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YVIUVYJJSZFGCX-LJQANCHMSA-N 1-[(3s)-3-[2-[4-(6-chloro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)C[C@H]1CCN1CC=C(C=2C3=CC=C(Cl)C=C3NC=2)CC1 YVIUVYJJSZFGCX-LJQANCHMSA-N 0.000 description 1
- -1 1-acetyl-2,3-dihydro-1H- indol-3-yl Chemical group 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000003392 indanyl group Chemical class C1(CCC2=CC=CC=C12)* 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- XRXDAJYKGWNHTQ-UHFFFAOYSA-N quipazine Chemical compound C1CNCCN1C1=CC=C(C=CC=C2)C2=N1 XRXDAJYKGWNHTQ-UHFFFAOYSA-N 0.000 description 1
- 229950002315 quipazine Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Recrystallisation Techniques (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200100732 | 2001-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307955B true ZA200307955B (en) | 2004-10-13 |
Family
ID=8160484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307955A ZA200307955B (en) | 2001-05-09 | 2003-10-13 | Treatment of ADHD. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7294638B2 (sk) |
| EP (1) | EP1387682A1 (sk) |
| JP (1) | JP2004528361A (sk) |
| KR (1) | KR20040007544A (sk) |
| CN (1) | CN1507351A (sk) |
| AR (1) | AR033287A1 (sk) |
| BG (1) | BG108400A (sk) |
| BR (1) | BR0209443A (sk) |
| CA (1) | CA2446652A1 (sk) |
| CO (1) | CO5540378A2 (sk) |
| CZ (1) | CZ20033197A3 (sk) |
| EA (1) | EA200301221A1 (sk) |
| HR (1) | HRP20030852A2 (sk) |
| HU (1) | HUP0400075A2 (sk) |
| IL (1) | IL158413A0 (sk) |
| IS (1) | IS6992A (sk) |
| MX (1) | MXPA03010136A (sk) |
| NO (1) | NO20034972L (sk) |
| NZ (1) | NZ528896A (sk) |
| PL (1) | PL367778A1 (sk) |
| SK (1) | SK15002003A3 (sk) |
| WO (1) | WO2002089797A1 (sk) |
| ZA (1) | ZA200307955B (sk) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003102097A1 (en) * | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | The hydrochloride of (s)-(+)-3-[1-[2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1h-indole |
| CA2585014A1 (en) * | 2004-10-22 | 2006-05-04 | Mark Froimowitz | Methylphenidate analogs and methods of use thereof |
| WO2009136410A2 (en) | 2008-04-19 | 2009-11-12 | Nisarga Biotech Pvt. Ltd. | Herbal composition for reducing add/adhd and method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| ZA9711376B (en) * | 1996-12-20 | 1998-07-21 | Lundbeck & Co As H | Indole or dihydroindole derivatives |
| AU2002230665A1 (en) * | 2000-12-06 | 2002-06-18 | Sepracor, Inc. | 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands |
-
2002
- 2002-04-29 AR ARP020101569A patent/AR033287A1/es not_active Application Discontinuation
- 2002-05-07 CA CA002446652A patent/CA2446652A1/en not_active Abandoned
- 2002-05-07 JP JP2002586932A patent/JP2004528361A/ja active Pending
- 2002-05-07 MX MXPA03010136A patent/MXPA03010136A/es unknown
- 2002-05-07 US US10/477,382 patent/US7294638B2/en not_active Expired - Lifetime
- 2002-05-07 EA EA200301221A patent/EA200301221A1/ru unknown
- 2002-05-07 CN CNA028095790A patent/CN1507351A/zh active Pending
- 2002-05-07 SK SK1500-2003A patent/SK15002003A3/sk unknown
- 2002-05-07 KR KR10-2003-7014554A patent/KR20040007544A/ko not_active Application Discontinuation
- 2002-05-07 EP EP02724146A patent/EP1387682A1/en not_active Withdrawn
- 2002-05-07 WO PCT/DK2002/000298 patent/WO2002089797A1/en not_active Application Discontinuation
- 2002-05-07 HU HU0400075A patent/HUP0400075A2/hu unknown
- 2002-05-07 NZ NZ52889602A patent/NZ528896A/xx unknown
- 2002-05-07 IL IL15841302A patent/IL158413A0/xx unknown
- 2002-05-07 CZ CZ20033197A patent/CZ20033197A3/cs unknown
- 2002-05-07 PL PL02367778A patent/PL367778A1/xx not_active Application Discontinuation
- 2002-05-07 BR BR0209443-6A patent/BR0209443A/pt not_active IP Right Cessation
-
2003
- 2003-10-13 ZA ZA200307955A patent/ZA200307955B/en unknown
- 2003-10-13 IS IS6992A patent/IS6992A/is unknown
- 2003-10-20 HR HR20030852A patent/HRP20030852A2/hr not_active Application Discontinuation
- 2003-11-07 NO NO20034972A patent/NO20034972L/no not_active Application Discontinuation
- 2003-11-27 CO CO03104809A patent/CO5540378A2/es not_active Application Discontinuation
- 2003-12-01 BG BG108400A patent/BG108400A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0209443A (pt) | 2004-08-03 |
| EA200301221A1 (ru) | 2004-04-29 |
| WO2002089797A8 (en) | 2004-03-25 |
| US20040152737A1 (en) | 2004-08-05 |
| HUP0400075A2 (hu) | 2004-04-28 |
| HRP20030852A2 (en) | 2005-06-30 |
| BG108400A (bg) | 2004-11-30 |
| MXPA03010136A (es) | 2004-03-10 |
| WO2002089797A1 (en) | 2002-11-14 |
| CN1507351A (zh) | 2004-06-23 |
| CA2446652A1 (en) | 2002-11-14 |
| JP2004528361A (ja) | 2004-09-16 |
| IL158413A0 (en) | 2004-05-12 |
| KR20040007544A (ko) | 2004-01-24 |
| CO5540378A2 (es) | 2005-07-29 |
| CZ20033197A3 (en) | 2004-06-16 |
| SK15002003A3 (sk) | 2004-05-04 |
| US7294638B2 (en) | 2007-11-13 |
| NZ528896A (en) | 2004-12-24 |
| PL367778A1 (en) | 2005-03-07 |
| EP1387682A1 (en) | 2004-02-11 |
| NO20034972D0 (no) | 2003-11-07 |
| AR033287A1 (es) | 2003-12-10 |
| IS6992A (is) | 2003-10-13 |
| NO20034972L (no) | 2003-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1087937C (zh) | 抑制阿尔茨海默症的药物 | |
| US6436938B1 (en) | Combination treatment for depression | |
| US6380199B1 (en) | Use of 5HT6 antagonists | |
| US6835728B2 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
| US7294638B2 (en) | Treatment of ADHD | |
| Safdieh et al. | A case of hyponatremia induced by duloxetine | |
| AU2002254875A1 (en) | Treatment of ADHD | |
| JP2006523650A (ja) | うつ病および／または不安の治療用のパロキセチンと４−（ｓ）−（４−アセチル−ピペラジン−１−イル）−２−（ｒ）−（４−フルオロ−２−メチル−フェニル）−ピペリジン−１−カルボン酸［１−（ｒ）−（３，５−ビス−トリフルオロメチル−フェニル）−エチル］メチルアミドとの組合せ | |
| MXPA05000791A (es) | Compuestos de 1-fenil-2-dimetilaminometil ciclohexano para la terapia de sintomas depresivos, dolor e incontinencia. | |
| JP2018203774A (ja) | 精神障害の治療における使用のためのイロペリドン代謝物 | |
| EP1942891B1 (en) | Novel combination of drugs as antidepressant | |
| CN1247578C (zh) | 含有2－芳基－8－氧化二氢嘌呤衍生物作为活性成分的痴呆症治疗剂 | |
| Chang et al. | Catatonia associated with coadministration of tramadol and meperidine | |
| KR20010099648A (ko) | 신규 조성물 | |
| US20070197592A1 (en) | Use of Paliperidone for the Treatment of Substance Abuse | |
| WO2005067909A1 (en) | Combination therapy with mecamylamine for the treatment of mood disorders | |
| AU4279599A (en) | Use of an nk-1 receptor antagonist for treating cognitive disorders | |
| WO2024059631A1 (en) | R-trihexyphenidyl for treatment of movement disorders | |
| Scates et al. | Focus on citalopram: A selective serotonin reuptake inhibitor for the treatment of depression | |
| US20090203738A1 (en) | Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia | |
| WO1999064006A1 (en) | Use of a nk-1 receptor antagonist for treating psychiatric disorders | |
| Hanna | Comments on guest editorial," Chronic fatigue syndrome, mast cells, and tricyclic antidepressants" | |
| JPH09110721A (ja) | Ｎｋ−１受容体アンタゴニストを用いる抗嘔吐治療用の組み合わせ | |
| AU2004200165A1 (en) | Methods and compositions for treating gastro-esophageal reflux disease |